RESEARCH

Open Access



Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Metaanalysis of Randomized controlled trials

Ubaid Khan^{1*}, Muhammad Mubariz², Yehya Khlidj³, Muhammad Moiz Nasir⁴, Shrouk Ramadan⁵, Fatima Saeed¹, Aiman Muhammad⁶ and Mohamed Abuelazm⁷

Abstract

Background Camostat mesylate, an oral serine protease inhibitor, is a powerful TMPRSS2 inhibitor and has been reported as a possible antiviral treatment against COVID-19. Therefore, we aim to assess the safety and efficacy of camostat mesylate for COVID-19 treatment.

Methods A systematic review and meta-analysis synthesizing randomized controlled trials from PubMed, Scopus, Embase, Cochrane, Web of Science, clinical trials.gov, and medrxiv until June 2023. The outcomes were pooled using Mean difference (MD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes. The protocol is registered in PROSPERO with ID CRD42023439633.

Results Nine RCTs, including 1,623 patients, were included in this analysis. There was no difference between camostat mesylate and placebo in producing negative PCR test results at 1–7 days (RR: 0.76, 95% CI: [0.54, 1.06] P=0.1), 8–14 days (RR: 1.02, 95% CI: [0.84, 1.23] P=0.87), or 15–21 days (RR: 0.99, 95% CI: [0.82, 1.19] P=0.90); clinical resolution of symptoms at 1–7 days (RR: 0.94 (95% CI: 0.58, 1.53) P=0.81), 8–14 days (RR: 0.91, 95% CI: [0.74, 1.11] P=0.33,), or 15–21 days (RR: 0.77, 95% CI: [0.40, 1.51] P=0.45); and time to symptom improvement (MD:-0.38 weeks (95% CI: [-1.42, 0.66] P=0.47, $l^2=85\%$).

Conclusion Camostat mesylate did not improve clinical outcomes in patients with COVID-19, compared to placebo. **Keywords** Camostat Mesylate, Covid-19, Pandemic, SARS-CoV-2, Review, Analysis

*Correspondence: Ubaid Khan ubaidkhanafridi@yahoo.com ¹King Edward Medical University, Lahore, Pakistan ²Akhtar Saeed Medical and Dental College, Lahore, Pakistan ³Faculty of medicine, Algiers University, Alger Centre, Algeria ⁴Dow University of health science, Karachi, Pakistan ⁵Faculty of medicine, Ain Shams University, Cairo, Egypt ⁶Khyber Girls Medical College, Peshawar, Pakistan ⁷Faculty of Medicine, Tanta University, Tanta, Egypt

Introduction

Coronavirus disease 2019 (COVID-19) is a novel coronavirus that originated in China's Hubei region and spread throughout the world in late 2019 [1–3]. On March 11th, 2020, the WHO classified COVID-19 as a pandemic. COVID-19 is extremely contagious and has put an enormous burden on healthcare systems around the world. Pharmacological treatment of infected patients is required until herd immunity is acquired by extensive viral outbreaks or an effective prophylactic vaccination, since social distance is not an effective long-term standalone method.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Current treatment of COVID-19 is primarily hospitalbased and directed at advanced disease, for example with remdesivir with FDA approval based on three pivotal trials [4–7], and corticosteroids such as dexamethasone [8, 9]. Furthermore, Monoclonal antibodies can be used in the outpatient setting but they are expensive, logistically challenging to administer, and have variable degrees of efficacy due to viral variants [9].

Despite the recent progress of antiviral drugs, further therapeutic alternatives are still required, especially for post-exposure prophylaxis and COVID-19 early treatment in outpatient settings. New pharmaceutical targets have been suggested as viable options for antiviral drugs against COVID-19. To clarify, viral replication and disease progression can be effectively stopped by blocking viral host cell entry. Previous experimental data [10–12] show that the SARS-CoV-2 spike (S) protein binds to target cells via the host cell factors angiotensin-converting enzyme 2 (ACE-2) and that S protein cleavage by the host cell surface trans-membrane protease serine 2 (TMPRSS2) allow entry into target cells.

Camostat mesylate has been used in clinical settings to treat pancreatitis and reflux esophagitis for over two decades [11-13]. Camostat mesylate molecules inhibit TMPRSS2 priming of S protein, a process that has been demonstrated to be both essential and sufficient for viral entry into respiratory epithelial cells [11, 12]. Also, COVID-19 infection of primary human lung epithelial cells was demonstrated to be inhibited by camostat mesylate. Camostat mesylate is a prodrug that, upon entering the bloodstream, rapidly converts to the pharmacologically active metabolite FOY-251, which inhibits TMPRSS2. FOY-251 has an EC50 of 178 nM against SARS-CoV-2 infection in Calu-3 lung cell culture [11]. Moreover, even at high dosages, it has few, mild adverse effects and is readily produced at low costs. Hence, camostat mesylate was predicted to be a good candidate for the treatment of COVID-19. This systematic review and meta-analysis aims to synthesize evidence from randomized controlled trials (RCTs), investigating the efficacy and safety of camostat mesylate for COVID-19 treatment.

Methodology

Protocol Registration

The Preferred Reporting Items for Meta-Analyses according to (PRISMA) guidelines [14] were followed for this meta-analysis. Our protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) with ID CRD42023439633.

Data source and search strategy

An electronic search of PubMed, Scopus, Embase, Cochrane, Web of Science, clinical trials.gov, and medrxiv was conducted from inception to June 2023 without any search restrictions. In addition, references from any retrieved trials were screened manually to identify potentially relevant articles. Further details regarding data source and search strategy are given in (Table S1).

Eligibility criteria

A PICO criterion was used to include RCTs: population (P): patients with COVID-19 regardless of the disease severity; intervention (I): camostat mesylate; control (C): placebo with or without the standard of care; and outcomes (O): primary outcomes of this review were the efficacy outcomes: all-cause mortality, PCR negative, clinical resolution of symptoms, time to symptom improvement, hospitalization duration, and intensive care unit (ICU) admission or mechanical ventilation. The secondary outcomes included safety outcomes: any adverse events, any serious adverse, elevated liver enzymes, and specific safety events.

Study selection

Three reviewers (A.I., S.R., & M.M.) independently screened the studies using Covidence [15] after duplicates were screened and removed automatically. The remaining studies were carefully assessed in accordance with the eligibility criteria. All studies were initially short-listed based on title and abstract, and subsequently, full-length articles were reviewed. Any discrepancies and conflicts between the selected studies were resolved by a U.K.

Data extraction

Four reviewers (A.I., S.R., M.M., & M.M.N.) extracted data independently, including baseline, efficacy, and safety data. Baseline data included number of participants in each, mean age, gender, mean body mass index (BMI), mean duration of symptoms, ordinal severity score, and comorbidity data. Efficacy data was recorded in terms of number of patients with negative PCR (at 1-7 days, 8-14 days, and 15-21 days or more), clinical resolution of symptoms (at 1-7 days, 8-14 days, and 15-21 days or more), time to improvement in symptoms, viral load at the end of follow up, duration of hospitalization, all-cause mortality, and ICU admission or mechanical ventilation. Safety data included the incidence of any adverse event, any serious adverse event, and specific adverse events. Conflicts were solved by mutual discussion between reviewers.

Risk of Bias and Certainty of evidence

Four reviewers (A.I., S.R., M.M., & F.S) independently assessed the quality of included studies using the modified Cochrane Collaboration's risk of bias tool for randomized controlled trials [16] Conflicts were solved by mutual discussion between reviewers.

To appraise the quality of evidence, two reviewers (M.A. and U.K.) utilized the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines [17, 18]. We considered inconsistency, imprecision, indirectness, publication bias, and risk of bias. The evaluation was carried out for each outcome, and the decisions made were justified and documented. Any discrepancies were settled through discussion.

We followed the confidence interval cutoffs provided by Cochrane consumers and communication "how to grade?" guidelines [19].

Statistical analysis

RevMan (version 5.3; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for all statistical analyses [20]. The results from trials were presented as risk ratios (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes with a 95% confidence interval (CI) and were pooled using a fixed-effects model in case of homogenous data and random effects model in case of heterogeneous data. According to the Cochrane Handbook (chapter nine) [21]., heterogeneity was considered significant if the alpha value of the Chi-square test is below 0.1, while the interpretation of the I-square test is as follows: (0–40%) not significant, (30–60%) moderate heterogeneity, (50– 90%) substantial heterogeneity, and (75–100%) considerable heterogeneity.

Results

Search results and study characteristics

The initial literature search yielded 816 studies after the removal of duplicate (n=151) and irrelevant studies (n=656), leaving nine RCTs for inclusion in the final quantitative and qualitative analysis. Out of total, 63 studies were excluded in full text screening with reason of exclusion mentioned in (Table S2). Finally, nine studies were included in the final analysis. Further details can be obtained from the PRISMA flowchart in (Fig. 1).

Included studies characteristics

Nine RCTs [22–30] were included in the final analysis with a total of 1,623 participants (n=912 in the camostat mesylate group and n=711 in the placebo group), with 52.7% of the patients being male. Most of the studies were conducted in the USA (n=4), followed by an equal number of trials from Sweden, Austria, Japan, Denmark, Belgium, and South Korea. Camostat mesylate and placebo were given as oral tablets. The mean duration of follow-up was 2.8 weeks. The definition and criteria for serious adverse events were different in each article so

we have explained it in Table S3 to make it clear. Further information about baseline study and patient characteristics are available in (Tables 1, 2), respectively.

Risk of Bias and Certainty of evidence

After a careful assessment using the Cochrane ROB 2.0 tool, six RCTs were concluded as having a low risk of bias [22–27], two showing some concerns [28, 30], and one with a high risk of bias [29].(Fig. 2). Certainty of evidence is demonstrated in detail in a GRADE evidence profile (Table 3). The details of all the domains which are assessed are mentioned in (Table S4-S12).

Efficacy outcomes

All-cause mortality

The analysis showed an insignificant difference between camostat mesylate and the placebo groups, and no significant heterogeneity was observed (RR: 0.55, 95% CI: [0.27, 1.10] P=0.09, I²=31%) (Fig. 3-A).

Negative PCR

There was no difference between both groups at 1–7 days (RR: 0.77, 95% CI: [0.55, 1.07] P=0.12, I²=0%), 8–14 days (RR: 1.03, 95% CI: [0.85, 1.24] P=0.80, I²=0%), and 15–21 days (RR: 1.04, 95% CI: [0.91, 1.20] P=0.52, I²=33%), without any observed significant heterogeneity (Fig. 3-B).

Clinical resolution of symptoms

There was no difference between both groups at 1–7 days (RR: 1.02, 95% CI: [0.78, 1.34] P=0.87, I^2 =49%), 8–14 days (RR: 0.90, 95% CI: [0.73, 1.10] P=0.30, I^2 =0%), and 15–21 days (RR: 0.77, 95% CI: [0.40, 1.50] P=0.45, I^2 =0%) without any observed significant heterogeneity (Fig. 4-A).

Time to Symptom Improvement

There was no difference between both groups (MD: -0.38 weeks, 95% CI: [-1.42, 0.66] P=0.47, I²=85%) (Fig. 4-B). Significantly high heterogeneity was observed (I²=85%, P=0.0002) which was resolved by removing Karolyi et al. by leave-one-out sensitivity analysis (I²=0%, P=0.88) (Table S13).

ICU admission or mechanical ventilation

There was no difference between both groups (RR: 0.55, 95% CI: [0.20, 1.53] P=0.25, $I^2=57\%$) (Fig. 4-C). Significant heterogeneity was observed which could not be resolved by a sensitivity analysis (Table S13).

Safety outcomes

There was no difference between both groups regarding the incidence of any adverse events (RR: 0.93, 95% CI: [0.67, 1.29] P=0.66, I²=80%), elevated liver enzymes (RR: 0.30, 95% CI: [0.07, 1.30] P=0.12, I²=0%), abdominal pain (RR: 0.57, 95% CI: [0.19, 1.73] P=0.32, I²=0%), and



Fig. 1 PRISMA flow chart of the screening process

pruritis (RR: 1.76, 95% CI: [0.43, 7.11] P=0.43, I^2 =0%). However, compared to the placebo group, the camostat mesylate group showed a significantly higher risk of any serious adverse events (RR: 1.77, 95% CI: [1.1, 2.83] P=0.02, I^2 =35%), and a lower risk of diarrhea (RR: 0.35, 95% CI: [0.18, 0.67] P=0.002, I²=41%) (Fig. 5). More details about serious adverse events in each study are given in table S13.

Statistically significant heterogeneity was observed in any adverse events outcome (I²=80%, p<0.0001). A

	Study Decim			Total Darticinante	mc	Moc.			Control	Drimany	Method of viral	Time of viral gradica-	Clinical	Eollow-
	information (mana		Severity		Form	Dose	Times of administration,	E		Outcome	eradication	tion assessment	resolution	d D
							Day	Dura- tion			assessment		assessment criteria	Duration
Chupp et al. 2022 [22]	Phase II, Double-Blind, RCT	USA	Outpatient Mild	70	Oral tablet	200 mg	Four	7 days	Placebo	Reduction in viral load.	Nasopharyngeal swab (RT-PCR)	0,2,4,6	N/A	4 weeks
Karolyi et al. 2022 [29]	Multi-Center open-label RCT	Austria	Hospitalized moderate to severe	201	Oral tablet	100 mg	Two	N/A	Lopinavir/ ritonavir	Time to sustained clinical improve- ment (≥48 h)	N/A	N/A	Seven-cate- gory ordinal scale	4 weeks
Jilg et al. 2023 [23]	Phase II RCT	NSA	Hospitalized Mild to moderate	216	Oral tablet	200 mg	Two	7 days	Placebo	Reduction in viral load	Nasopharyngeal swab (RT-PCR)	3,7,14	Likert scale	4 weeks
Kim et al. 2022 [28]	Double- blinded, Phase II RCT	South Korea	Mild to moderate	342	Oral tablet	N/A	N/A	14 days	Placebo	Time to clinical improvement through 14 days	N/A	7	Likert scale	2 weeks
Tobback et al. 2022 [24]	Phase II RCT	Belgium	Outpatient Mild	06	Oral tablet	300 mg	Three	5 days	Placebo	Reduction in viral load	Nasopharyngeal swab (RT-PCR)	1,5,10	Likert scale	5 days
Gunst et al. 2021 [26]	Double-blind- ed RCT	Denmark & Sweden	Hospitalized moderate to severe	205	Oral tablet	200 mg	Three	5 days	Placebo	Time to clinical improvement	Oropharyngeal swabs for all patients and blood samples for some patients	Baseline and day 5	N/A	4 weeks
Kinoshita et al. 2022 [25]	Mult-center, double-blind- ed, RCT"	Japan	Mild to moderate	- 155	Oral tablet	600 mg	Three	14 days	Placebo	Time to first two consecutive negative SARS- CoV-2 test at hospitals local laboratory.	Nasopharyngeal swab (RT-PCR)	Daily tests were performed	N/A	2 weeks
NCT04524663 [30]	Double- blinded, Phase II RCT	USA	Mild to moderate	49	Oral tablet	N/A	NA	10 days	Standard sup- portive care	Time from randomization to first two consecu- tive negative PCR test results	Nasopharyngeal swab (RT-PCR)	NA	A/A	4 weeks
NCT04583592 [27]	Quadruple- blinded RCT	NSA	Mild to moderate	295	Oral tablet	200 mg	Four	14 days	Placebo	Disease progres- sion at day 28	N/A	N/A	N/A	N/A
RCT: Randomized cc	ontrolled trial, U:	SA: United State	s of America; N/A:	not available										

Khan et al. BMC Infectious Diseases (2024)

Page 5 of 15

leave-one-out sensitivity analysis was conducted; however, no single study could be found responsible for it (Table S13).

Discussion

The present systematic review and meta-analysis showed that camostat mesylate is overall ineffective in improving the clinical outcomes of COVID-19 patients while increasing the risk of any serious adverse events. Hence, camostat mesylate exhibited no superiority to placebo in reducing the risk of mortality and ICU admission or mechanical ventilation events. Similarly, it did not accelerate either the clinical recovery (clinical resolution of symptoms and time to symptom improvement) or the viral clearance (time for PCR negativation). Therefore, the current RCTs-based evidence suggests that camostat mesylate when given as monoantiviral therapy for COVID-19 patients may have no particular utility whether in mild, moderate, or severe forms.

Death in patients with acute SARS-CoV-2 infection results from several causes, including multiple organ dysfunction syndrome, nosocomial superinfection (mainly ventilator-associated pneumonia), refractory hypoxemia/ pulmonary fibrosis (secondary to extensive lung damage), and fatal ischemic events affecting venous (e.g., pulmonary embolism) or arterial (e.g., stroke and myocardial infarction) circulation [31]. For an antiviral drug to reduce the risk of these events it should prevent the progression to severe COVID-19 and hospitalization by early eradication of infection such as the FDA-approved drugs' combination nirmatrelvir/ritonavir (Paxlovid) which is also based on anti-protease activity [32, 33].

Since the use of camostat mesylate did not affect the features of disease progression (infection's clinical evolution, viral load kinetics, ICU admission, and mechanical ventilation) reduction in mortality rates is unlikely to be achieved. Additionally, the absence of a significant decrease in hospitalization rates signifies that camostat mesylate has low benefits in patients at risk for severe COVID-19. Furthermore, the no change in time for clinical recovery among camostat-treated groups indicates that this drug may be a non-useful strategy to treat COVID-19 outpatients with both moderate and mild forms.

Moreover, the earlier control of viral replication is essential for an antiviral drug to be effective in COVID-19 patients [34]. On one hand, this would prevent the tissular injury induced by either SARS-CoV-2 or its associated inflammation, and on the other hand, it would decrease the infectivity of patients, thereby minimizing disease transmission. The anti-SARS-CoV-2 activity of camostat mesylate was speculated from its potential to block TMPRSS2-mediated viral fusion; thus, inhibiting viral replication in host cells, as shown by in vitro human cell and animal studies [35, 36]. The fact that camostat mesylate did not induce significant acceleration in PCR negativation time likely reflects its failure to effectively contribute to viral clearance and replication arrest/ prevention.

Mechanistically, this seems to be due to two main reasons: (i) the non-pharmacological effectiveness of camostat mesylate as a TMPRSS2 inhibitor administered in monotherapy, or (ii) the non-utility of TMPRSS2 inhibition as an exclusive strategy to prevent viral invasion (the most likely probability). Hence, studies on the molecular pharmacology of camostat mesylate indicated that it may not be the optimal ligand to block TMPRSS2 activity [37–39]. Notably, it has been revealed that camostat has lesser inhibition potential compared to a similar TMPRSS2 blocker nafamostat as the latter forms significantly higher amounts of enzyme-substrate stable complexes [39]. Remarkably, the pharmacological potency of camostat mesylate was shown to be 10-fold less than that of nafamostat mesylate [2]. Further results from animal studies concluded that nafamostat is a better candidate for the prevention of SARS-CoV-2 TMPRSS2-mediated entry compared to camostat [40]. Simultaneously, it has been recently demonstrated that SARS-CoV-2 can enter target cells without the need for ACE2 and TMPRSS2 participation through "cell-to-cell fusion" mechanism. Notably, the involvement of TMPRSS2 in this mechanism was found to be dispensable suggesting that SARS-CoV-2 exhibits TMPRSS2-independent cellular invasion strategies [41].

Moreover, even in the absence of TMPRSS2, SARS-CoV-2 has an alternative route of entry by endocytosis and transportation into endolysosomes where it is released to the cytosol via the action of acid-activated cathepsin L protease [42]. Therefore, SARS-CoV-2 can use these pathways to escape from camostat mesylate and other specific inhibitors of TMPRSS2. This possibility is more pronounced with the novel SARS-CoV-2 variants (i.e., Omicron) which no longer rely on TMPRSS-2 as a fusogenicity factor [43]. Consequently, targeting TMPRSS2 alone is not sufficient to fully prevent penetration of SARS-CoV-2 to host cells. Another potential disadvantage of targeting TMPRSS2 is that this protein displays an interindividual structural variability with some functional variants being expressed at relatively high frequencies among many human populations [44]. There are also interindividual quantitative variations in TMPRSS2 levels secondary to genetic polymorphisms across populations [45]. Both qualitative and quantitative variations in TMPRSS2 may alter the individuals' response to camostat mesylate and similar drugs by potentially decreasing ligand potency and efficiency.

Besides the low efficacy profile, analysis of the safety profile indicated some concerns with camostat mesylate

Page / of I	5
-------------	---

Number of Age (Years)	Study ID
Baseline characteristics of the participan	Table 2

Table 2 Base	line character	ristics c	of the particit	pants																		
Study ID	Number o patients ir	of Ag ∩ Μ€	e (Years) an (SD)	Ger (Ma	lder le) N. (%)	Body mass index, Mea	buration of a symptoms,	Ordi	nal Sever	ity Score N. (9	(%	Comor	bidities <i>N</i> .	(%)								
	each grou	<u>و</u>				(SD)	Mean (SD)															
	CM Control	M D	Control	QM	Control	CM Control	CM Control	m		4	ъ	Smol	ding	MQ	-	NT	0	OPD	Ä	thm	Lan Lar	diovascu- disease
								δ	Control	CM Control	CM Control	Ð	Control	E C		E U		ž ŭ Z	5 5 -	t Ö	S 	Con- trol
Chupp et al. 2022 [22]	35 35	44.1 (14.(5) 44.1 (12.0)	(62.9)	20 (57.1)	N/A N/A	41.1 35.8 (25.6) (22.4)	N/A	N/A	N/A N/A	N/A N/A	N/A	E VN	2.9)	3.6) (2	0 4 28.6) (1	1.4)	0 (6:	9 (0) (25)	7 (20	0.0) (0.0)	0 (0:0)
Karolyi et al. 2022 [29]	101 100	56.6 (17.2	5 60.7 2) (12.6)	67 (66)	67 (67)	30.4 30.1 (5.6) (5.7)	5.34 4.34 (3.01) (3.76)	15 (15)	20 (20)	64 59 (63) (59)	22 21 (22) (21)	V/A	N/A	20 20)	34) 4 34) (2	7 58 47) (5	8 (2)	6) 24		V/N ∀	9	2
Jilg et al. 2023 [23]	109 107	38.3 (15)	38.6 (14.27	7) 46 (42.2)	52 · (48.5)	27.96 27.7 (5.55) (5.26)	5.66 5.33 (2.25) (3)	N/A	N/A	N/A N/A	N/A N/A	N/A	N/A	A/A	A A/N	N A/I	N	N K	A'N	A N	N/N	N/A
Kim et al. 2022 [28]	172 170	52.1 (14.:	5 50.68 (15.1 55)	14) 95 (55.25	87 (51.18) 3	24.95 24.87 (3.66) (3.76)	N/A N/A	94 (54.65)	02) (60.00)	N/A N/A	N/A N/A	25 (26.04)	25 :: (27.78) (28 1 29.17) (19 5 21.11) (<u>5</u>	0 5, 52.08) (6	4 1 50.00) (1	.04) (2.	22) N	N/N ∀	(13.	11 54) (12.22
Tobback et al. 2022 [24]	61 29	38 (21)	36.6 (22.6)	28 (45.9)	13 1 (44.8)	23.8 25 (2.8) (3.9)	1 26 (83.6) (89.7)	N/A	N/A	N/A N/A	N/A N/A	19 (31.1)	9 (31.0) (1.6)	~ 6	N AV	N N	N K	A'N	N/N ⊲	N/A	N/A
Gunst et al. 2021 [26]	137 68	62.7 (18.(, 63.3)) (14.4)	82 (60)	41 (60)	27.8 29.2 (5.4) (5.2)	NA NA	47 (34)	22 (32)	81 39 (59) (57)	9 7 (07) (10)	NA	AN NA	21 15) (14 5 21) (5	0 2 [.] 36) (3	1 1.0) (1	4 0 2 7	18 (13	9 (13	29	10 (15)
Kinoshita et al. 2022 [25]	78 77	55.7 (18.	, 56.1 3) (18.2)	35 (44.9)	43 1 (55.8)	24.5 23.9 (5.2) (3.7)	3.3 3.5 (1.2) (1.1)	78 (100)	77 (100)	NA NA	NA NA	AN	en en	15 1 19.2) (12.2 15.6) (3	4 2(30.8) (2	0 1 26.0) (1	1 14 (1) (1;	F NA	NA	4 (5.1)	4 (5.2)
NCT04524663 [30]	: 25 24	37.5 (13.:) 40.5 5) (14.3)	15 (60)	17 (70.8)	28.7 27.7 (6.7) (4.1)	4.6 4.4 (2.6) (1.0)	ΥN	NA	NA NA	NA NA	AN	NA	- AN	A A	N Al	Z M	A A	۸	NA	NA	ΝA
NCT04583592 [27]	: 194 101	NA	NA	86 (44.3)	40 1 (39.6)	NA NA	NA NA	AN	٩N	NA NA	NA NA	AN	NA	1 AN	A A	N Al	Z A	2 V	۹N	AN	NA	ΡN
N. Number; SC). Standard Dev	viation;	CM. Camosta	it mesyla	ite																	



Fig. 2 Quality assessment of risk of bias in the included trials. The upper panel presents a schematic representation of risks (low=red, unclear=yellow, and high=red) for specific types of biases of each of the studies in the review. The lower panel presents risks (low=red, unclear=yellow, and high=red) for the subtypes of biases of the combination of studies included in this review.

due to a higher risk of any serious adverse events in the treated groups compared to controls. The mechanisms of this molecule's toxicity are unclear; however, since TMPRSS2 is ubiquitously expressed in the human body its inhibition may result in systemic undesirable effects. Additionally, camostat mesylate has a broad action on other proteases involved in multiple functions such as blood pressure control and renal function, inflammation, and coagulation [46]; which when inhibited in COVID-19 patients (especially those with severe forms) may lead to more harms than goods. Worth mentioning that camostat mesylate has anti-diarrheic effects as it was shown to normalize intestinal hyperpermeability in rats which could explain the lower susceptibility to diarrhea in COVID-19 patients compared to placebo [43].

Table 3 GRADE evidence p	profile									
Certainty assessment						Summary	of findings			
Participants Risk of bia (studies)	s Inconsistency	Indirectness	Imprecision	Publica- tion	Overall certainty of	Study ever	ıt rates (%)	Relative effect	Anticipated a effects	bsolute
Follow-up				bias	evidence	With Placebo	With Camostat Mesylate	(95% CI)	Risk with Placebo	Risk differ- ence with Camostat Mesylate
All-cause mortality 674 very seriou: (5 RCTs)	s ^a not serious	very serious ^b	very serious ^c	none	OOO Very low	19/301 (6.3%)	14/373 (3.8%)	RR 0.55 (0.27 to 1.10)	63 per 1,000	28 fewer per 1,000 (from 46 fewer
PCR Negative – 1–7 days 941 not serious (5 RCTs)	not serious	not serious	very serious ^c	none		56/426 (13.1%)	59/515 (11.5%)	RR 0.77 (0.55 to 1.07)	131 per 1,000	to 6 more) 30 fewer per 1,000 (from 59 fewer to 9 more)
PCR Negative – 8–14 days 773 not serious (5 RCTs)	not serious	not serious	serious ^d	none	⊕⊕⊕ O Moderate	108/340 (31.8%)	147/433 (33.9%)	RR 1.03 (0.85 to 1.24)	318 per 1,000	10 more per 1,000 (from 48 fewer to 76 more)
PCR Negative – 15–21 days 678 not serious (5 RCTs)	not serious	not serious	not serious	none	⊕⊕⊕⊕ ^{High}	122/276 (44.2%)	201/402 (50.0%)	RR 1.04 (0.91 to 1.20)	442 per 1,000	18 more per 1,000 (from 40 fewer to 88 more)
Clinical resolution of sympto 373 not serious (3 RCTs)	ms – 1–7 days not serious	not serious	very serious ^c	none		61/168 (36.3%)	67/205 (32.7%)	RR 1.02 (0.78 to 1.34)	363 per 1,000	7 more per 1,000 (from 80 fewer to 123 more)
Clinical resolution of sympto 303 not serious (2 RCTs)	ms – 8–14 days not serious	not serious	very serious ^d	none		73/133 (54.9%)	71/170 (41.8%)	RR 0.90 (0.73 to 1.10)	549 per 1,000	55 fewer per 1,000 (from 148 fewer to 55 more)
Clinical resolution of sympto 269 not serious (2 RCTs) Time to symptom improvem	ms – 15–21 days not serious ent	not serious	very serious ^d	none		16/117 (13.7%)	14/152 (9.2%)	RR 0.77 (0.40 to 1.50)	137 per 1,000	31 fewer per 1,000 (from 82 fewer to 68 more)

Table 3 (conti	inued)										
Certainty assess	iment						Summary o	of findings			
Participants (studies)	Risk of bias	Inconsistency	Indirectness	Imprecision	Publica- tion	Overall certainty of	Study even	t rates (%)	Relative effect	Anticipated a effects	bsolute
Follow-up					bias	evidence	With Placebo	With Camostat Mesylate	(95% Cl)	Risk with Placebo	Risk differ- ence with Camostat Mesylate
945 (4 RCTs)	serious ^e	very serious ^f	serious ^g	very serious ^h	none	⊕⊖⊖⊖ Very low	437	508	1		MD 0.38 lower (1.42 lower to 0.66 higher)
(3 RCTs)	serious ⁱ	serious	serious ^k	very serious ^h	none	HOOO Very low	21/244 (8.6%)	18/315 (5.7%)	RR 0.55 (0.20 to 1.53)	86 per 1,000	39 fewer per 39 fewer per 1,000 (from 69 fewer to 46 more)
(9 RCTs) (9 RCTs)	not serious	very serious ^f	not serious	not serious	none		310/709 (43.7%)	329/844 (39.0%)	RR 0.94 (0.74 to 1.21)	437 per 1,000	26 fewer per 1,000 (from 114 fewer to 92 more)
Any serious adv 1262 (7 RCTs)	erse events not serious	not serious	not serious	serious ^h	none	⊕⊕⊕⊖ Moderate	21/580 (3.6%)	45/682 (6.6%)	RR 1.77 (1.10 to 2.83)	36 per 1,000	28 more per 1,000 (from 4 more to 66 more)
CI: confidence inte <i>Explanations</i> a. Karolyi et al. is to b. Karolyi et al. is ti c. Wide confidence d. Low number of e. Karolyi et al. is o f. 12 > 75%	frual; MD: mean dii fhigh risk of overa a only study that a interval that doe: events<300 event fhigh risk of overa	fference; RR: risk ratio II bias and constitute 73 used lopinavir/ritonavir s not exclude the risk of s II bias and constituting :	.7% of the outcome po as a control, constitut appreciable harm/ber 27.3% of the outcome	ooled data ing 73.7% of the out nefit, with a low num pooled data	come pooled	data data					
ט. המוטועו כו מו. וש יו	ווב סוווא זימים איומי	חפבת ומלווומגוו/וווגמיוימגוי	מא מ בטוונוטו, בטוואנושי	וווט בויט אי טוווב טעני	יחווים איווה	uata					

Khan et al. BMC Infectious Diseases

k. Karolyi et al. is the only study that used lopinavir/ritonavir as a control, constituting 44.1% of the outcome pooled data

i. Karolyi et al. is of high risk of overall bias and constitute 44.1% of the outcome pooled data h. Wide confidence interval that does not exclude the risk of appreciable harm/benefit

j. l2 > 50%

A- All-Cause Mortality

A-All-Cause Iv	Turtan	LL Y	Disasi			Diels Defie			Diel: Defin
Chudu an Cubanaun	Camos	Tatal	Place	Tatal	Mainht	RISK Rauo	Veer		RISK Ratio
Study of Subgroup	Events	Total	Events	Total	weight	M-H, Fixed, 95% CI	rear		WI-H, FIXED, 95% CI
Gunst et al	8	135	4	66	26.3%	0.98 [0.31, 3.13]	2021		
Chupp et al	U	35	0	35	70 70	Not estimable	2022		_
Karoiyi et al	6	101	15	100	13.1%	0.40 [0.16, 0.98]	2022	-	
Kinoshita et al	0	77	0	76		Not estimable	2022		
NCT04524663	0	25	0	24		Not estimable	2023		
Total (95% CI)		373		301	100.0%	0.55 [0.27, 1.10]			
Total events	14		19						
Heterogeneity: Chi ² =	1 45 df=	1 (P =	0 23): P=	31%				 	
Test for overall effect:	7 = 1.68 (P = 0.0	9)					0.1	0.2 0.5 1 2 5 10
B- Negative P(R		-,						Favours Camostat Favours Placebo
D inegative i	Camos	tat	Place	ho		Risk Ratio			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H Fixed 95% CL	Year		M_H Fixed 95% Cl
1111.7 days	Litento	Total	Licito	Total	Toight	In-11, 11xcu, 55% ci	Tour		
Chunn at al	o	24	4	24	1 206	2 00 00 88 80 20	2022		
Chupp et al Korolui ot ol	0 5	400	4	400	1.2.70		2022		
Karuiyi etal Kinaahita atal	10	123	47	123	2.470		2022		
Kinushila et al	12				5.2%	0.71 [0.36, 1.38]	2022		
Jilg et al	2	187	2	91	0.0%	1.05 [0.15, 7.26]	2023		
NC104583592	32	194	25	101	10.0%	0.67 [0.42, 1.06]	2023		
Subiotal (95% CI)		515		420	19.5%	0.77 [0.55, 1.07]			
l otal events	59		56						
Heterogeneity: Chi ² =	3.55, df =	4 (P =	0.47); ²=	:0%					
Test for overall effect:	Z=1.56 (P = 0.1	2)						
1.1.2 8 - 14 days									
Chupp et al	17	34	18	34	5.5%	0.94 [0.60, 1.50]	2022		
Karolyi et al	21	43	23	43	7.0%	0.91 [0.60, 1.38]	2022		
Kinoshita et al	31	77	30	76	9.2%	1.02 [0.69, 1.51]	2022		
Jilg et al	1	85	1	86	0.3%	1.01 [0.06, 15.91]	2023	•	
NCT04583592	77	194	36	101	14.5%	1.11 [0.81, 1.52]	2023		
Subtotal (95% CI)		433		340	36.5%	1.03 [0.85, 1.24]			•
Total events	147		108						
Heterogeneity: Chi ² =	0.69, df=	4 (P =	0.95); l² =	:0%					
Test for overall effect:	Z= 0.25 (P = 0.8	0)						
1.1.3 15-21 days									
Tobback et al	23	61	7	29	2.9%	1.56 (0.76, 3.21)	2022		
Chunn et al	27	34	28	34	8.6%	0.96 (0.77, 1.22)	2022		
NCT04524663	14	22	21	24	61%	0.73 [0.51 1.03]	2022		
NCT04523592	136	104	65	101	26.1%	1 00 00 07 1 70	2023		
lila et el	100	Q1	1	90	0.3%		2023		
Subtotal (95% CI)	4	402		276	44.0%	1.04 [0.91, 1.20]	2025		•
Total evente	201	102	100	210	11.070	101 [010 1, 1120]			
Hataraganaity: Chi2-	201 6.00 df-	1 (P -	122 0.20\+12=	2200					
Test for overall effect:	7 = 0.64	+v⊂ - Έ=05	0.20), r = (2)	. 22.20					
reaction over all ellett.	2 - 0.04 (,							
Total (95% CI)		1350		1042	100.0%	0.98 [0.88, 1.10]			♦
Total events	407		286						
Heterogeneity: Chi ² =	12.51. df	= 14 (P	= 0.57):	² = 0%				<u> </u>	
Test for overall effect:	Z = 0.30 (P = 0.7	7)					0.1	U.2 U.5 1 2 5 10
Test for subgroup diff	erences:	Chi ^z = 1	2.88, df =	2 (P =	0.24), I ^z =	30.6%			Favours Camostat Favours Placedo

Fig. 3 Forest plots of the primary efficacy outcome, RR: risk ratio, MD: mean difference, CI: confidence interval

Strengths and limitations

To the best of our knowledge, this is the first metaanalysis that assesses the safety and efficacy of camostat mesylate in COVID-19 patients. Therefore, this paper presents the gold-standard evidence on this topic including all available RCTs that met our criteria to reach the highest accessible quality of evidence. We analyzed data from a large number (n=1,623) of patients and provided key findings. However our paper is undermined by the following: first, we included three non-peer-reviewed reports, including a preprint ref and two unpublished RCTs data [27, 30]. Second, the included studies suffered from significant heterogeneity in the camostat dosing regimen, which can affect our findings. Third, all the

A- Clinical Resolution of Symptoms

	Camo	stat	Place	bo		Risk Ratio			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year		M-H, Fixed, 95% Cl
1.2.1 1-7 days									
Chupp et al	12	35	19	35	12.2%	0.63 (0.36, 1.09)	2022		
Kim et al	50	109	40	104	26.4%	1.19 [0.87, 1.64]	2022		
Tobback et al	5	61	2	29	1.7%	1.19 [0.25, 5.77]	2022		
Subtotal (95% CI)		205		168	40.3%	1.02 [0.78, 1.34]			•
Total events	67		61						
Heterogeneity: Chi ² =	3.88, df=	: 2 (P =	0.14); l² :	= 49%					
Test for overall effect:	Z=0.16	(P = 0.8	37)						
1.2.2 8-14 days									
Kim et al	67	109	70	104	46.1%	0.91 [0.75, 1.12]	2022		
Tobback et al	4	61	3	29	2.6%	0.63 (0.15, 2.65)	2022		
Subtotal (95% CI)		170		133	48.7%	0.90 [0.73, 1.10]			•
Total events	71		73						
Heterogeneity: Chi ^z =	0.25, df=	: 1 (P =	0.61); l² :	= 0%					
Test for overall effect:	Z=1.04	(P = 0.3)	30)						
4 0 0 45 04 1									
1.2.3 15-21 days									
Tobback et al	2	61	2	29	1.7%	0.48 [0.07, 3.21]	2022	•	
Jilg et al	12	91	14	88	9.2%	0.83 [0.41, 1.69]	2023		
Subtotal (95% CI)		152		117	10.9%	0.77 [0.40, 1.50]			
Total events	14	-	16	ALC: NO LOOP					
Heterogeneity: Chi ² =	0.29, df=	: 1 (P =	0.59); l²:	= 0%					
Test for overall effect:	Z=0.76	(P = 0.4)	15)						
Total (05% CI)		537		440	400.08	0.02 [0.70 4 40]			
Total (95% CI)	450	521		418	100.0%	0.95 [0.79, 1.10]			
l otal events	152	o /5	150	~~				ĩ.	
Heterogeneity: Chif =	5.23, df =	: б (Р =	0.51); F:	= 0%				0.1	0.2 0.5 1 2 5 10
Test for overall effect:	Z = 0.81	(P = 0.4	12)	o (D		~~			Favours Camostat Favours Placebo
lest for subgroup diff	erences:	Chi ² =	0.89, df =	2 (P =	U.64), I ² =	:0%			

B- Time to Symptom Improvement

				Mean Difference		Mean Difference	
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI	
Gunst et al	-1.2	0.7601	18.8%	-1.20 [-2.69, 0.29]	2021		
Karolyi et al	1	0.3403	27.3%	1.00 [0.33, 1.67]	2022	-	
Kim et al	-0.79	0.3484	27.1%	-0.79 [-1.47, -0.11]	2022		
Jilg et al	-0.8	0.3722	26.7%	-0.80 [-1.53, -0.07]	2023		
Total (95% CI)			100.0%	-0.38 [-1.42, 0.66]		•	
Heterogeneity: Tau ² =	0.91; Chi ² = 19.62,	df = 3 (P	= 0.0002)); I² = 85%		-10 -5 0 5	10
restior overall effect:	$\angle = 0.72 (P = 0.47)$					Favours Camostat Favours Placebo	
C ICII Admis	ion or Mooh	ninal	Vontil	otion			

C-ICU Admission or Mechanical Ventilation

	Camos	stat	Place	bo		Risk Ratio			Ris	k Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year		M-H, Ran	dom, 95	% CI		
Gunst et al	14	137	8	68	55.9%	0.87 [0.38, 1.97]	2021						
Karolyi et al	4	101	13	100	44.1%	0.30 [0.10, 0.90]	2022	2		-			
Kinoshita et al	0	77	0	76		Not estimable	2022						
Total (95% CI)		315		244	100.0%	0.55 [0.20, 1.53]							
Total events	18		21										
Heterogeneity: Tau ² =	0.32; Ch	i ² = 2.3	1, df = 1 (P = 0.1	3); l² = 57	%					+	<u>_</u>	10
Test for overall effect:	Z=1.15	(P = 0.2	25)					0.1	Favours Camosta	at Favo	urs Plac	cebo	10



A-Any Advers	e Evei	its	201011-0					
Study or Subgroup	Camos	tat	Placet	Total	Weight	Risk Ratio	Vast	Risk Ratio
Gunst et al	38	77	22	76	11 7%	1 70 11 12 2 501	2021	
Karolvi et al	36	101	59	100	13.8%	0.60 [0.44, 0.82]	2022	
Kinoshita et al	25	77	31	76	11.7%	0.80 [0.52, 1.21]	2022	
Kim et al	95	164	101	163	16.1%	0.93 [0.78, 1.12]	2022	-+-
Tobback et al	59	61	23	29	15.8%	1.22 [1.01, 1.48]	2022	
Chupp et al	13	35	9	35	7.3%	1.44 [0.71, 2.94]	2022	*
NCT04524663	2	25	13	24	2.8%	0.15 [0.04, 0.59]	2023	•
NCT04583592 file et al	17	195	13	107	7.0%	0.66 [0.34, 1.31]	2023	
ongeral	44	109	39	107	13.2%	1.11 [0.79, 1.55]	2023	
Total (95% CI)		844		709	100.0%	0.94 [0.74, 1.21]		+
Total events	329		310					
Heterogeneity: Tau ² =	0.09; Chi	² = 34.0)8, df = 8	(P < 0.)	0001); l² =	77%		
Test for overall effect:	Z= 0.45 (P = 0.6	6)					Favours Camostat Favours Placebo
B-Any Seriou	s Adve	rse l	Events	i				
	Camo	stat	Place	ebo		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Tota	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
Gunst et al	27	77	8	76	33.1%	3.33 [1.62, 6.86]	2021	
Chupp et al	1	35	0	35	i 2.1%	3.00 [0.13, 71.22]	2022	
Kim et al	0	164	0	163		Not estimable	2022	
Kinoshita et al	1	77	0	76	2.1%	2.96 [0.12, 71.58]	2022	
UIIG ET BI	6	109	5	107	20.8%	1.18 [0.37, 3.74]	2023	·
NC104524663	10	25	3	24	14.7%	0.14 [0.01, 2.53]	2023	
NC104063592	10	195	5	95	21.3%	1.02 [0.36, 2.89]	2023	T
Total (95% CI)		682		580	100.0%	1.77 [1.10. 2.83]		-
Total events	45		21		NUMBER OF TRACTOR	,		-
Heterogeneity: Chi ² =	: 7.67, df:	= 5 (P =	: 0.18); F	= 35%				
Test for overall effect	Z = 2.37	(P = 0.	02)	0.02.02.0				U.1 U.2 U.5 1 2 5 10 Favours Camostat Favours Placebo
C-Elevated L	iver E	nzvn	ies					
and commentations and the second s	Camo	stat	Place	bo		Risk Ratio		Rick Ratio
Study or Subaroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed. 95% CI
Tobback et al	1	61	0	20	8 7%	1 45 [0 06 34 50]	2022	
NCT04583592	Ó	195	1	99	25.6%	0.17 [0.01, 4.14]	2023	
NCT04524663	1	25	5	24	65.7%	0.19 [0.02, 1.53]	2023	
						and a solution statement		
Total (95% CI)		281		152	100.0%	0.30 [0.07, 1.20]		
Total events	2	-	6	12/20				r
Heterogeneity: Chi ² =	1.25, df=	2 (P =	0.54); l²:	= 0%				0.005 0.1 1 10 200
rest for overall effect:	∠=1.71	(ピ= 0.0	18)					Favours Camostat Favours Placebo
D- Abdominal	Pain							
	Camo	stat	Diaco	ho		Rick Patio		Rick Ratio
Study or Subaroup	Events	Total	Events	Total	Weight	M-H, Fixed. 95% Cl	Year	M-H, Fixed. 95% Cl
Karolvi et al	1	101	3	100	38.3%	0.33 [0 03 3 12]	2022	
Kinoshita et al	1	77	1	76	12.8%	0.99 [0.06, 15,50]	2022	Trade of Concession of Concess
Tobback et al	1	61	. 1	29	17.2%	0.48 [0.03, 7.34]	2022	
Chupp et al	1	35	0	35	6.4%	3.00 [0.13, 71.22]	2022	
NCT04583592	0	195	1	99	25.3%	0.17 [0.01, 4.14]	2023	
Total (95% CI)		469		339	100.0%	0.57 [0.19, 1.73]		
l'otal events	4	1.0	6	0.00				r r r r
Heterogeneity: Chi ² =	2.00, df=	:4(P= /0-0/	∪.73); I²÷ 22\	= U%				0.005 0.1 1 10 200
rest for overall effect:	∠= 0.99	(~ = 0.)	52)					Favours Camostat Favours Placebo
E- Pruritis	0	atat	P!			Dials D-41-		Dials D-41-
Study or Subgroup	Camo	stat	Place	DO Toto	Moinht	RISK Ratio	Voor	RISK Ratio
Study of Subgroup	Events	Total	Events	Total	vveight	wi-H, Fixed, 95% Cl	rear	IWI-H, FIXE0, 95% CI
Unupplet al Tophaskistici	3	35	1	35	33.1%	3.00 [0.33, 27.46]	2022	
NCT04583592	1	195	1	29 QQ	44.970 71 Q.04	0.55 [0.08, 10.08] 1.53 [0.08, 37.22]	2022	
	1.0	, 55	U	29	21.070	7.00 [0.00, 07.20]	2020	
Total (95% CI)		291		163	100.0%	1.76 [0.43, 7.11]		
Total events	6		2					
Heterogeneity: Chi ² =	0.49, df=	2 (P =	0.78); l²:	= 0%				
Test for overall effect:	Z=0.79	(P = 0.4	43)					Favours Camostat Favours Placebo
F-Diarrhea								
	Camo	stat	Place	bo		Risk Ratio		Risk Ratio
Study or Subaroun	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
Study of Subgroup	7	61	4	29	17.1%	0.83 [0.26, 2.62]	2022	
Tobback et al		26	1	35	4.7%	0.33 [0.01, 7.91]	2022	
Tobback et al Chupp et al	0	30		110	00.5%	0.09 (0.02, 0.39 <u>)</u>	2022	
Tobback et al Chupp et al Karolyi et al	0 2	101	21	70	0.004	1 07 10 40 04 001	- CH 7 7	
Tobback et al Chupp et al Karolyi et al Kinoshita et al	0 2 2	101 77	21 1	76	3.2%	1.97 [0.18, 21.32]	2022	
Tobback et al Chupp et al Karolyi et al Kinoshita et al NCT04524663 NCT04583592	0 2 2 1 1	101 77 25	21 1 2 0	76 24 99	3.2% 6.4% 2.1%	1.97 [0.18, 21.32] 0.48 [0.05, 4.95] 1.53 [0.06, 37, 23]	2022	
Tobback et al Chupp et al Karolyi et al Kinoshita et al NCT04524663 NCT04583592	0 2 2 1 1	101 77 25 195	21 1 2 0	76 24 99	3.2% 6.4% 2.1%	1.97 [0.18, 21.32] 0.48 [0.05, 4.95] 1.53 [0.06, 37.23]	2023 2023	
Tobback et al Chupp et al Karolyi et al Kinoshita et al NCT04524663 NCT04583592 Total (95% CI)	0 2 2 1 1	101 77 25 195 494	21 1 2 0	76 24 99 363	3.2% 6.4% 2.1%	1.97 [0.18, 21.32] 0.48 [0.05, 4.95] 1.53 [0.06, 37.23] 0.35 [0.18, 0.67]	2023 2023	→
Tobback et al Chupp et al Karolyi et al NCT04524663 NCT04524663 NCT04583592 Total (95% CI) Total events	0 2 2 1 1 13	101 77 25 195 494	21 1 2 0 29	76 24 99 363	3.2% 6.4% 2.1% 100.0%	1.97 [0.18, 21.32] 0.48 [0.05, 4.95] 1.53 [0.06, 37.23] 0.35 [0.18, 0.67]	2023 2023	→ 1
Tobback et al Chupp et al Karolyi et al Kinoshita et al NCT04524663 NCT04524565 NCT04583592 Total (95% CI) Total events Heterogeneity: Chi [#] =	, 0 2 1 1 1 8.42, df=	101 77 25 195 494 5 (P =	21 1 2 0 29 0.13); F	76 24 99 363 = 41%	3.2% 6.4% 2.1% 100.0%	1.97 [0.18, 21.32] 0.48 [0.05, 4.95] 1.53 [0.06, 37.23] 0.35 [0.18, 0.67]	2023 2023	
Tobback et al Chupp et al Karolyi et al Kinoshita et al NCT04524663 NCT04583592 Total (95% CI) Total events Heterogeneity: Chi₹= Test for overall effect:	0 2 1 1 13 8.42, df= Z= 3.13	101 77 25 195 494 : 5 (P = (P = 0.1	21 1 2 0 29 0.13); F 002)	76 24 99 363 = 41%	3.2% 6.4% 2.1% 100.0%	1.97 [0.18, 21.32] 0.48 [0.05, 4.95] 1.53 [0.06, 37.23] 0.35 [0.18, 0.67]	2023 2023	0.005 0.1 1 10 200 Favours Camostat Favours Placebo

Fig. 5 Forest plot of the safety outcomes, RR: risk ratio, CI: confidence interval

included studies recruited patients with mild to moderate COVID-19, with only Gunst et al. and Karolyi et al. [26, 29], recruiting hospitalized patients with moderate to severe disease; therefore, our results may not be generalizable for severe COVID-19.

Implications and future perspectives

Targeting viral entry is a well-established strategy to fight viral diseases such as HIV and influenza virus infections; however, its benefit in COVID-19 remains questionable and is not yet supported by robust quality of evidence. Until full data becomes available, the results in this study do not exclude the usefulness of camostat mesylate in the context of COVID-19 infection as co-administration with other synergistic antiviral drugs may boost its efficacy profile. Since furin, another transmembranous enzyme involved in the proteolytic processing of SARS-CoV-2 is necessary for TMPRSS2-independent fusion (i.e., cellto-cell fusion), the combination of furin and TMPRSS2 inhibitors may enhance the overall preventive effects on viral entry and infectivity [13, 38]. Nevertheless, the constant changes in SARS-CoV-2 cellular invasion pathways may not facilitate the development of the most adequate combination for viral entry inhibitors. Importantly, the presence of safety concerns with camostat mesylate use among COVID-19 patients should justify more caution and strict patient monitoring in future evaluations. Based on these concerns and the lack of proof of effectiveness, current guidelines should recommend against the use of camostat mesylate in COVID-19 patients outside the context of clinical trials.

Conclusion

The current evidence does not support the efficacy of camostat mesylate in treating COVID-19 infection. Rather, it indicates some safety concerns that should be considered before further testing this drug in large-scale trials. Nevertheless, since the available data is incomplete more RCTs are still required to conclude the therapeutic benefit of camostat mesylate in COVID-19. At the same time, it might also be worthy to continue investigating the utility of viral entry inhibitors as potential treatment for COVID-19 by focusing on other TMPRSS2 inhibitors with greater pharmacological potency, agents with TMPRSS2-independent activity, or effective synergistic combinations of both.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12879-024-09468-w.

Supplementary Material 1

Acknowledgements

None.

Author contributions

M.A. conceived the idea. M.M. and S.R. designed the research workflow. U.K. and A.M. searched the databases. S.R., M.M., and A.M. screened the retrieved records. Four reviewers S.R., M.M., F.S., and A.M. extracted data independently extracted relevant data, assessed the quality of evidence, and U.K. resolved the conflicts. U.K. performed the analysis. Y.K., M.M.N., F.S., and S.R. wrote the final manuscript. M.A. supervised the project. All authors have read and agreed to the final version of the manuscript. I also declare that persons who have made substantial contributions to the work reported in the manuscript, including those who provided editing and writing assistance but who are not authors, are named in the Acknowledgments section of the manuscript does not include Acknowledgments, it is because the authors have not received substantial contributions for monauthors.

Funding

We received no funding for this study.

Data availability

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Declarations

Ethics approval and consent to participate Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare no competing interests.

Received: 22 October 2023 / Accepted: 3 June 2024 Published online: 19 July 2024

References

- Khan S et al. Emergence of a novel coronavirus, severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic options. J Clin Microbiol, 2020. 58(5).
- Deslandes A, et al. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020;55(6):106006.
- Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020;20(2):124–7.
- Beigel JH, et al. Remdesivir for the treatment of Covid-19 final report. N Engl J Med. 2020;383(19):1813–26.
- Goldman JD, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827–37.
- Horby P, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
- Spinner CD, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 days in patients with moderate COVID-19: a Randomized Clinical Trial. JAMA. 2020;324(11):1048–57.
- Johnson RM, Vinetz JM. Dexamethasone in the management of covid 19. BMJ. 2020;370:m2648.
- Verderese JP, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus Disease 2019 (COVID-19): a real-world experience. Clin Infect Dis. 2022;74(6):1063–9.
- Kreutzberger AJB, et al. Synergistic block of SARS-CoV-2 infection by Combined Drug Inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease. J Virol. 2021;95(21):e0097521.
- Hoffmann M, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021;65:103255.

- 12. Hoffmann M et al. Nafamostat Mesylate blocks activation of SARS-CoV-2: New Treatment option for COVID-19. Antimicrob Agents Chemother, 2020. 64(6).
- Motoo Y. Antiproteases in the treatment of chronic pancreatitis. Jop. 2007;8(4 Suppl):533–7.
- 14. Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicating references. Syst Rev. 2021;10(1):38.
- 16. Higgins JP, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
- Guyatt GH, et al. What is quality of evidence and why is it important to clinicians? BMJ. 2008;336(7651):995–8.
- Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
- Cochrane Consumers and Communication, https://cccrg.cochrane.org/ author-resources
- Reyman J. Book review: St.amant, Kirk, & Zemliansky, Pavel, editors. (2005). internet-based workplace communications: Industry and academic applications. hershey, PA: Information science publishing. Journal of Business and Technical Communication. 2007;21(4):442–5. doi:10.1171.
- 21. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions 2008.
- 22. Chupp G, et al. A phase 2 Randomized, Double-Blind, placebo-controlled trial of oral Camostat Mesylate for Early Treatment of COVID-19 outpatients showed shorter illness course and attenuation of loss of smell and taste. medRxiv; 2022.
- Jilg N, et al. One week of oral Camostat Versus Placebo in Nonhospitalized adults with mild-to-moderate coronavirus Disease 2019: a randomized controlled phase 2 trial. Clin Infect Dis. 2023;77(7):941–9.
- 24. Tobback E, et al. Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial. Int J Infect Dis. 2022;122:628–35.
- Kinoshita T, et al. A multicenter, double-blind, randomized, parallelgroup, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med. 2022;20(1):342.
- Gunst JD, et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. EClinicalMedicine. 2021;35:100849.
- 27. Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT) clinicaltrials.gov/https://classic.clinicaltrials.gov/ct2/history/ NCT04583592?V_9=View.
- Kim YS, et al. A Double-Blind, randomized, Placebo-Controlled, phase II clinical study to evaluate the efficacy and safety of Camostat Mesylate (DWJ1248) in adult patients with mild to moderate COVID-19. Antimicrob Agents Chemother. 2023;67(1):e0045222.
- 29. Karolyi M, et al. Camostat Mesylate Versus Lopinavir/Ritonavir in hospitalized patients with COVID-19-Results from a Randomized, controlled, open label, platform trial (ACOVACT). Front Pharmacol. 2022;13:870493.

- Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003) clinicaltrials govhttps://classic.clinicaltrials.gov/ ct2/show/NCT04524663.
- Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (paxlovid) for COVID-19: a rapid review and meta-analysis. J Med Virol. 2023;95(2):e28441.
- Tian H, et al. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: an updated meta-analysis and trial sequential analysis. Rev Med Virol. 2023;33(5):e2473.
- Hoffmann M et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv, 2020.
- Abuelazm M, et al. The Effect of Nitazoxanide on the clinical outcomes in patients with COVID-19: a systematic review and Meta-analysis of Randomized controlled trials. Clin Drug Investig. 2022;42(12):1031–47.
- 35. Breining P, et al. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2021;128(2):204–12.
- 36. Li K, et al. The TMPRSS2 inhibitor Nafamostat reduces SARS-CoV-2 Pulmonary infection in mouse models of COVID-19. mBio. 2021;12(4):e0097021.
- Reuter N et al. SARS-CoV-2 spike protein is capable of inducing cell-cell fusions independent from its receptor ACE2 and this activity can be impaired by furin inhibitors or a subset of monoclonal antibodies. Viruses, 2023. 15(7).
- Koch J, et al. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. Embo j. 2021;40(16):e107821.
- Meng B, et al. Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706–14.
- Ortiz-Fernández L, Sawalha AH. Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. Genes Immun. 2020;21(4):269–72.
- Li F, et al. Distinct mechanisms for TMPRSS2 expression explain organspecific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021;12(1):866.
- 42. Maekawa A, et al. Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009;27(1):181–9.
- Yuan L, et al. Camostat mesilate inhibits pro-inflammatory cytokine secretion and improves cell viability by regulating MFGE8 and HMGN1 in lipopolysaccharide-stimulated DF-1 chicken embryo fibroblasts. PeerJ. 2021;9:e12053.
- 44. Kastenhuber ER et al. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Elife, 2022. 11.
- Zhao J, et al. A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats. Eur J Pharmacol. 2011;654(3):289–94.
- Assylbekova A, et al. Camostat does not inhibit the proteolytic activity of Neutrophil Serine proteases. Volume 15. Pharmaceuticals (Basel); 2022. 5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.